Dr. Suchitra S-Holgersson

Dr. Suchitra S-Holgersson |Clyto Access

Sahlgrenska Science Park

Keynote Speaker

Expertise: Liver Diseases, Biomaterials, Autoantibodies, , Stem Cell Biology, Biotechnology, Phosphorylation

Biography:

Dr. Suchitra Sumitran-Holgersson earned her Doctor of Medical Sciences degree in Clinical Immunology at the Karolinska Institutet in 1991, and became an Associate Professor in 2000. In 2008, she joined the Sahlgrenska hospital at the Gothenburg University as the Professor of Transplantation Biology. She has contributed to more than 80 articles in peer-reviewed journals and 15 book chapters and has seven scientific patents to her credit.Her research interests include understanding mechanisms of allograft rejections, stem cell engraftment and tissue engineering of organs with stem cells.

Presentation:

Title: Creating organs using nature’s own scaffolding matrix and human stem cells

Abstract: Different pathological conditions such as congenital organ absence, severe organ injuries, end-stage organ failure and malignancy-related organ removal, have few effective therapeutic options apart from a whole organ transplant, that, however, often meets with a serious shortage of suitable donor organs. To solve these clinical issues we are developing a novel tissue engineering approach with a multi-disciplinary team of highly qualified and experienced clinicians, stem cell and molecular biologists, bio technologists, materials and surface scientists. A recent strategy in tissue/organ engineering, is the procedure of decellularizing a whole donor organ to obtain a complex 3D-biomatrix-scaffold maintaining the intrinsic vascular network, that is subsequently recellularized with recipient's autologous organ-specific differentiated cells or/and stem cells, to build a potentially functional biological substitute. Such a strategy has been clinically used by us in pioneering studies to replace blood vessels in patients with portal vein thrombosis. In another approach, we are also using naturally-derived matrices or even natural/polymer-composite materials to produce 3D-printed scaffolds for either cell-free or autologous cell-seeded tissue engineering procedures. The strategic goal is to facilitate dissemination, transfer and translation of knowledge from research findings into potentially improved clinical therapeutics through policies, interventions, services and products.

Related Conferences :

Global Forum on Transplantation Research and Technologies